For: | Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85 [PMID: 30815374 DOI: 10.5306/wjco.v10.i2.75] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm |
Number | Citing Articles |
1 |
Kei Muro, Taylor Salinardi, Arvind Rup Singh, Teresa Macarulla. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers 2020; 12(4): 844 doi: 10.3390/cancers12040844
|
2 |
Hélène Bellio, Nicolas Roussot, Aurélie Bertaut, Alice Hervieu, Sylvie Zanetta, Zoe Tharin, Julie Vincent, Leila Bengrine, Audrey Hennequin, Jean-Florian Guion, Axelle Boudrant, Thomas Collot, Francois Ghiringhelli, Jean-David Fumet. FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial. Future Oncology 2025; 21(6): 699 doi: 10.1080/14796694.2025.2461446
|
3 |
Koji Ando, Hironaga Satake, Mototsugu Shimokawa, Hisateru Yasui, Yuji Negoro, Tatsuya Kinjo, Junya Kizaki, Kenji Baba, Hiroyuki Orita, Keiji Hirata, Sanae Sakamoto, Akitaka Makiyama, Hiroshi Saeki, Akihito Tsuji, Hideo Baba, Eiji Oki. A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer. International Journal of Clinical Oncology 2025; 30(3): 514 doi: 10.1007/s10147-025-02701-9
|
4 |
Tomas Buchler, Igor Kiss, Jana Hornova, Ondrej Fiala, Marketa Wiesnerova, Michal Svoboda, Jiri Silar, Katerina Kopeckova, Alexandr Poprach, Jindrich Finek, Lubos Petruzelka, Bohuslav Melichar. Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted Oncology 2020; 15(2): 193 doi: 10.1007/s11523-020-00705-1
|
5 |
Eleonora Lai, Stefano Cascinu, Mario Scartozzi. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.637823
|
6 |
Raquel Claramunt García, Carmen Lucía Muñoz Cid, Andrés Sánchez Ruiz, Juan Francisco Marín Pozo. Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience. European Journal of Clinical Pharmacology 2022; 78(2): 287 doi: 10.1007/s00228-021-03235-5
|
7 |
Pu Ge, Abudurosuli Reyila, Xin‐yi Li, Si‐yu Liu, Yi‐xuan Jiang, Ya‐jie Yang, Xia‐lei Li, Ying Bian. Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA‐Compliant single‐arm Meta‐Analysis of noncomparative clinical studies and randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 2022; 47(6): 798 doi: 10.1111/jcpt.13610
|